PEOPLE - Eragen makes appointment:
This article was originally published in Clinica
Executive Summary
Molecular diagnostics firm Eragen (Madison, Wisconsin) has appointed Miguel Blanc as vice-president of corporate development. With more than ten years' experience in this specialist area, Mr Blanc joins the firm from GE Healthcare, where he was manager of global business development and played a role in several major acquisitions for the $3bn biosciences division during his tenure there. His list of achievements includes completing the strategic assessment and due diligence for GE's entry into the life sciences market through the $11bn-acquisition of Amersham in 2004, and being instrumental in the (ultimately aborted) $8.13bn acquisition of Abbott Labs' diagnostics and POC divisions.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.